Analytical and clinical validation of an RNA sequencing-based assay for quantitative, accurate evaluation of a molecular signature response classifier in rheumatoid arthritis-Reference-Cited by-同舟云学术

Analytical and clinical validation of an RNA sequencing-based assay for quantitative, accurate evaluation of a molecular signature response classifier in rheumatoid arthritis

Published:2021-11-02 Issue:11 Volume:21 Page:1235-1243
ISSN:1473-7159
Container-title:Expert Review of Molecular Diagnostics
language:en
Short-container-title:Expert Review of Molecular Diagnostics

Author:

Jones Alex¹,Rapisardo Sarah²,Zhang Lixia¹,Mellors Theodore¹,Withers Johanna B.¹^ORCID,Gatalica Zoran²,Akmaev Viatcheslav R.¹

Affiliation:

1. Data Science, Scipher Medicine Corporation, Waltham, MA, USA

2. Laboratory Operations, Scipher Medicine Corporation, Waltham, MA, USA

Funder

Corporation

Publisher

Informa UK Limited

Subject

Genetics,Molecular Biology,Molecular Medicine,Pathology and Forensic Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737159.2021.2000394

Reference51 articles.

1. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

2. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

3. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

4. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AI based on evolutionary computation yields algorithmic biomarker summary of a randomized rheumatoid arthritis clinical trial, accurately predicting individual patient outcomes, enabling precision medicine;2024-01-30

2. Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid Arthritis;Rheumatology and Therapy;2023-11-10

3. Age, Sex, Metabolic and Pharmacologic Factors May Predict Nonresponse Status to Rheumatoid Arthritis Therapies;In Vivo;2023

4. Patient outcomes improve when a molecular signature test guides treatment decision-making in rheumatoid arthritis;Expert Review of Molecular Diagnostics;2022-10-03

5. Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritis;Expert Opinion on Biological Therapy;2022-04-23